Clinical trial
Artificial Intelligence-Based Disease Management in the Vulnerable Period of Heart Failure, An Observational Study to Evaluate Patient Speech and Voice in the Vulnerable Phase of Heart Failure
NCT05544006 is registered in ClinicalTrials.gov with Albert Saglik Hizmetleri ve Ticaret A.S. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Artificial Intelligence-Based Disease Management in the Vulnerable Period of Heart Failure, An Observational Study to Evaluate Patient Speech and Voice in the Vulnerable Phase of Heart Failure
- Lead sponsor
- Albert Saglik Hizmetleri ve Ticaret A.S.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- October 26, 2022
- Completion date
- April 2, 2023
- Enrollment
- 76 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.